<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39331434</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1998-3689</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Indian journal of ophthalmology</Title><ISOAbbreviation>Indian J Ophthalmol</ISOAbbreviation></Journal><ArticleTitle>Clinicopathological presentations of eyelid malignancy in COVID era versus pre-COVID era.</ArticleTitle><Pagination><StartPage>1442</StartPage><EndPage>1447</EndPage><MedlinePgn>1442-1447</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/IJO.IJO_3332_23</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The coronavirus disease 2019 (COVID-19) pandemic led to overall interrupted medical care, resulting in disease progression and morbidity. The study aimed to evaluate clinicopathological presentations and severity of eyelid malignancy during the COVID era, comparing the results with patients presented during pre-COVID era and evaluating the reasons for delayed presentation in patients with advanced eyelid malignancy in the COVID-era.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a comparative, ambispective observational study. Data regarding demographic, clinical, histopathology, and treatment modalities of confirmed cases of eyelid malignancy admitted during the period from March 2020 to September 2022 (defined as COVID era group) were collected and compared with retrospectively collected data from March 2017 to March 2020 (defined as pre-COVID era group). COVID era patients were further categorized as localized and advanced disease. Patients with advanced eyelid malignancy during COVID era were further subjected to a questionnaire to evaluate the reasons for delayed presentation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 115 patients of eyelid malignancy were studied [COVID era group 40 (35%) and pre-COVID era group 75 (65%)]. A statistically significant increase in the duration of disease (P = 0.0001) and advanced tumor T-stage (P = 0.03) was noticed in the COVID era group. Demographic, histopathology, and ocular morbidity details were similar in both groups. The common reasons that led to delay in presentation and treatment in advanced T-stage patients during the COVID era were fear of acquiring COVID, lockdown, and lack of medical facilities.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">During the COVID-19 pandemic, both hospital- and patient-related factors contributed to delay in presentation, leading to advanced-stage disease indicating need of triaging of eyelid malignancy in the event of such pandemics in future.</AbstractText><CopyrightInformation>Copyright © 2024 Copyright: © 2024 Indian Journal of Ophthalmology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mounica</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Oculoplasty and Oncology Services (Dr. Rajendra Prasad Centre for Ophthalmic Sciences), All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pushker</LastName><ForeName>Neelam</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Oculoplasty and Oncology Services (Dr. Rajendra Prasad Centre for Ophthalmic Sciences), All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kashyap</LastName><ForeName>Seema</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Ocular Pathology (Dr Rajendra Prasad Centre of Ophthalmic Sciences), All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sen</LastName><ForeName>Seema</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Ocular Pathology (Dr Rajendra Prasad Centre of Ophthalmic Sciences), All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agrawal</LastName><ForeName>Sahil</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Oculoplasty and Oncology Services (Dr. Rajendra Prasad Centre for Ophthalmic Sciences), All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meel</LastName><ForeName>Rachna</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Oculoplasty and Oncology Services (Dr. Rajendra Prasad Centre for Ophthalmic Sciences), All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bajaj</LastName><ForeName>Mandeep S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Oculoplasty and Oncology Services (Dr. Rajendra Prasad Centre for Ophthalmic Sciences), All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bakhshi</LastName><ForeName>Sameer</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology (Institute Rotary Cancer Hospital), All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Indian J Ophthalmol</MedlineTA><NlmUniqueID>0405376</NlmUniqueID><ISSNLinking>0301-4738</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005142" MajorTopicYN="Y">Eyelid Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005143" MajorTopicYN="N">Eyelids</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>18</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>11</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39331434</ArticleId><ArticleId IdType="doi">10.4103/IJO.IJO_3332_23</ArticleId><ArticleId IdType="pii">02223307-202472100-00012</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed 2020;91:157–60.</Citation></Reference><Reference><Citation>Rabbone I, Schiaffini R, Cherubini V, Maffeis C, Scaramuzza A; Diabetes Study Group of the Italian Society for Pediatric Endocrinology and Diabetes. Has COVID-19 delayed the diagnosis and worsened the presentation of type 1 diabetes in children? Diabetes Care 2020;43:2870–2.</Citation></Reference><Reference><Citation>Romero J, Valencia S, Guerrero A. Acute appendicitis during coronavirus disease 2019 (COVID-19): Changes in clinical presentation and CT findings. J Am Coll Radiol 2020;17:1011–3.</Citation></Reference><Reference><Citation>Schirmer CM, Ringer AJ, Arthur AS, Binning MJ, Fox WC, James RF, et al. Delayed presentation of acute ischemic strokes during the COVID-19 crisis. J Neurointerv Surg 2020;12:639–42.</Citation></Reference><Reference><Citation>O’Reilly-Shah VN, Van Cleve W, Long DR, Moll V, Evans FM, Sunshine JE, et al. Impact of COVID-19 response on global surgical volumes: An ongoing observational study. Bull World Health Organ 2020;98:671–82.</Citation></Reference><Reference><Citation>Jaworska N, Schalm E, Kersen J, Smith C, Dorman J, Brindle M, et al. The impact of delayed nonurgent surgery during the COVID-19 pandemic on surgeons in Alberta: A qualitative interview study. CMAJ Open 2023 4;11:E587–96.</Citation></Reference><Reference><Citation>Patt D, Gordan L, Diaz M, Okon T, Grady L, Harmison M, et al. Impact of COVID-19 on cancer care: How the pandemic is delaying cancer diagnosis and treatment for American seniors. JCO Clin Cancer Inform 2020;4:1059–71.</Citation></Reference><Reference><Citation>Gold J. Surging health care worker quarantines raise concerns as coronavirus spreads. Kaiser Health News, 2020. Available from: https://health.wusf.usf.edu/health-news-florida/2020-03-09/surging-health-care-worker-quarantines-raise-concerns-as-coronavirus-spreads/. [Last accessed on 2023 Dec 14].</Citation></Reference><Reference><Citation>Englum BR, Prasad NK, Lake RE, Mayorga-Carlin M, Turner DJ, Siddiqui T, et al. Impact of the COVID-19 pandemic on diagnosis of new cancers: A national multicenter study of the veterans affairs healthcare system. Cancer 2022;128:1048–56.</Citation></Reference><Reference><Citation>Figueroa JD, Gray E, Pashayan N, Deandrea S, Karch A, et al.Breast Screening Working Group (WG2) of the Covid-19 and Cancer Global Modelling Consortium The impact of the Covid-19 pandemic on breast cancer early detection and screening. Prev Med 2021;151:106585. doi: 10.1016/j.ypmed. 2021.106585.</Citation></Reference><Reference><Citation>Sha Z, Chang K, Mi J, Liang Z, Hu L, Long F, et al. The impact of the COVID-19 pandemic on lung cancer patients. Ann Palliat Med 2020;9:3373–8.</Citation></Reference><Reference><Citation>Morris EJA, Goldacre R, Spata E, Mafham M, Finan PJ, Shelton J, et al. Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: A population-based study. Lancet Gastroenterol Hepatol 2021;6:199–208.</Citation></Reference><Reference><Citation>Hasegawa N, Rusakevich A, Bernicker E, Teh BS, Schefler A. Comparison of tumor size and gene expression at presentation in uveal melanoma patients before and during the COVID-19 pandemic. Ocul Oncol Pathol 2022;8:156–60.</Citation></Reference><Reference><Citation>Bansal R, Aishwarya A, Rao R, Christy MC, Sen M, Regani H, et al. Impact of COVID-19 nationwide lockdown on retinoblastoma treatment and outcome: A study of 476 eyes of 326 children. Indian J Ophthalmol 2021;69:2617–24.</Citation></Reference><Reference><Citation>Fontes Junior VC, Fernandes AG, Morales MC, Belfort Neto R. The impact of the COVID-19 pandemic on the diagnosis and treatment of ocular cancer. Arq Bras Oftalmol 2023;86:127–30.</Citation></Reference><Reference><Citation>Ul Kadir SM, Rani Mitra M, Rashid R, Nuruddin M, Hassan Khan MK, Haider G, et al. Clinicopathological analysis and surgical outcome of eyelid malignancies: A study of 332 cases. J Skin Cancer 2022;2022:4075668. doi: 10.1155/2022/4075668.</Citation></Reference><Reference><Citation>Silverman N, Shinder R. What’s new in eyelid tumors. Asia Pac J Ophthalmol 2017;6:143–52.</Citation></Reference><Reference><Citation>Cook BE, Bartley GB. Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmsted County, Minnesota. Ophthalmology 1999;106:746–50.</Citation></Reference><Reference><Citation>Burgic M, Iljazovic E, Vodencarevic AN, Burgic M, Rifatbegovic A, Mujkanovic A, et al. Clinical characteristics and outcome of malignant eyelid tumors: A five-year retrospective study. Med Arch 2019;73:209–12.</Citation></Reference><Reference><Citation>Kaliki S, Bothra N, Bejjanki KM, Nayak A, Ramappa G, Mohamed A, et al. Malignant eyelid tumors in India: A study of 536 Asian Indian patients. Ocul Oncol Pathol 2019;5:210–9.</Citation></Reference><Reference><Citation>Kale SM, Patil SB, Khare N, Math M, Jain A, Jaiswal S. Clinicopathological analysis of eyelid malignancies - A review of 85 cases. Indian J Plast Surg 2012;45:22–8.</Citation></Reference><Reference><Citation>Takamura H, Yamashita H. Clinicopathological analysis of malignant eyelid tumor cases at Yamagata university hospital: Statistical comparison of tumor incidence in Japan and in other countries. Jpn J Ophthalmol 2005;49:349–54.</Citation></Reference><Reference><Citation>Jahagirdar SS, Thakre TP, Kale SM, Kulkarni H, Mamtani M. A clinicopathological study of eyelid malignancies from central India. Indian J Ophthalmol 2007;55:109–12.</Citation></Reference><Reference><Citation>London JW, Fazio-Eynullayeva E, Palchuk MB, Sankey P, McNair C. Effects of the COVID-19 pandemic on cancer-related patient encounters. JCO Clin Cancer Inform 2020;4:657–65.</Citation></Reference><Reference><Citation>de Joode K, Dumoulin DW, Engelen V, Bloemendal HJ, Verheij M, van Laarhoven HWM, et al. Impact of the coronavirus disease 2019 pandemic on cancer treatment: The patients’ perspective. Eur J Cancer 2020;136:132–9.</Citation></Reference><Reference><Citation>Sud A, Jones ME, Broggio J, Loveday C, Torr B, Garrett A, et al. Collateral damage: The impact on outcomes from cancer surgery of the COVID-19 pandemic. Ann Oncol 2020;31:1065–74.</Citation></Reference><Reference><Citation>Troesch A, Hoellwerth M, Forchhammer S, Del Regno L, Lodde G, Turko P, et al. The impact of the COVID-19 pandemic on the diagnosis of cutaneous melanomas: A retrospective cohort study from five European skin cancer reference centres. J Eur Acad Dermatol Venereol 2023;37:922–31.</Citation></Reference><Reference><Citation>Anderson S, Rigney K, Hayes L, Ryan PC, Chaitanya V, Jacob PT, et al. A retrospective cohort study of bladder cancer following the COVID-19 pandemic: Are patients presenting with more aggressive disease? Ann Med Surg (Lond) 2022;81:104430. doi: 10.1016/j.amsu. 2022.104430.</Citation></Reference><Reference><Citation>Khan H, Johnson C, Malwankar J, Battafarano R, Yang S, Broderick S, et al. The COVID-19 era is associated with delays in esophageal cancer diagnosis and treatment. J Surg Res 2023;285:100–6.</Citation></Reference><Reference><Citation>Karamani L, McLean AL, Kamp MA, Mayer TE, Müller W, Dinc N, et al. Tumor size, treatment patterns, and survival in neuro-oncology patients before and during the COVID-19 pandemic. Neurosurg Rev 2023;46:226.</Citation></Reference><Reference><Citation>Ricci F, Fania L, Paradisi A, Di Lella G, Pallotta S, Sobrino L, et al. Delayed melanoma diagnosis in the COVID-19 era: Increased breslow thickness in primary melanomas seen after the COVID-19 lockdown. J Eur Acad Dermatol Venereol 2020:e778-9.</Citation></Reference><Reference><Citation>Gualdi G, Porreca A, Amoruso GF, Atzori L, Calzavara-Pinton P, De Tursi M, et al. The effect of the COVID-19 lockdown on melanoma diagnosis in Italy. Clin Dermatol 2021;39:911–9.</Citation></Reference><Reference><Citation>Jangir MK, Kochar A, Khan NA, Jaju M. Profile of eyelid tumours: Histopathological examination and relative frequency at a tertiary centre in north–west Rajasthan. Delhi J Ophthalmol 2017;28:30–5.</Citation></Reference><Reference><Citation>Krishnamurthy H, Tanushree V, Venkategowda HT, Archana S, Mobin G, D’Silva A, et al. Profile of eyelid tumors at tertiary care institute in Karnataka: A 5-years survey. J Evol Med Dent Sci 2014;3:11818–33.</Citation></Reference><Reference><Citation>Sihota R, Tandon K, Betharia SM, Arora R. Malignant eyelid tumors in an Indian population. Arch Ophthalmol 1996;114:108–9.</Citation></Reference><Reference><Citation>Hoellwerth M, Kaiser A, Emberger M, Brandlmaier M, Laimer M, Egger A, et al. COVID-19-induced reduction in primary melanoma diagnoses: Experience from a dermatopathology referral center. J Clin Med 2021;10:4059. doi: 10.3390/jcm10184059.</Citation></Reference><Reference><Citation>Wang H, Elsheikh M, Gilmour K, Cohen V, Sagoo MS, Damato B, et al. Impact of COVID-19 pandemic on eye cancer care in United Kingdom. Br J Cancer 2021;124:1357–60.</Citation></Reference><Reference><Citation>Bermudez-Castellanos I, Saornil Álvarez MA, Almaraz Gómez A, Villoria-Diaz S, García Álvarez C. Impact of COVID-19 on a rare disease (uveal melanoma) in a national reference unit of intraocular tumors in Spain. Arch Soc Esp Oftalmol (Engl Ed) 2023;98:254–8.</Citation></Reference><Reference><Citation>Magrath I, Steliarova-Foucher E, Epelman S, Ribeiro RC, Harif M, Li CK, et al. Paediatric cancer in low-income and middle-income countries. Lancet Oncol 2013;14:e104–16.</Citation></Reference><Reference><Citation>Peter N, Bandyopadhyay S, Lakhoo K, on Children GH. Protocol: Impact of the COVID-19 pandemic on paediatric patients with cancer in low-income, middle-income and high-income countries: Protocol for a multicentre, international, observational cohort study. BMJ Open 2021;11:e045679. doi: 10.1136/bmjopen-2020-045679.</Citation></Reference><Reference><Citation>Gupta AK, Meena JP, Seth R. Reasons for missed chemotherapy appointments in retinoblastoma patients undergoing chemotherapy: A report from a tertiary care hospital from India. Cancer Rep 2020;3:e1279. doi: 10.1002/cnr2.1279.</Citation></Reference><Reference><Citation>Tiwari V, Yogi V, Ghori HU, Singh OP, Peepre K, Yadav S, et al. Identifying the factors causing delayed presentation of cancer patients to a government medical college of Central India. J Clin Diagn Res 2015;9:XC09.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>